Following a seven-day trial last year, a jury found that Teva willfully induced infringement of claims of U.S. Patent No. RE40,000 from January 2008 to April 2011 (“skinny label period”) and from May ...
Supreme Court set to consider cert. petition on generic drug use of “skinny labels” to avoid infringing method of use patents. Court expected to consider cert. petition during court conference on May ...
The federal government re-ignited a controversial proposal to give generic drug makers the power to unilaterally update product labels to reflect new safety information, a proposal that drew criticism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback